Clinical Trial

Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

Name: Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases — clinical trial record (NCT07283315)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

Evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Paediatric B cell-related autoimmune diseases

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-02.

Trial Details

NCT Number	NCT07283315
Lead Sponsor	The Children's Hospital of Zhejiang University School of Medicine Collaborators: Rui Therapeutics
Conditions	Paediatric B Cell-related Autoimmune Diseases, Autoimmune Diseases, CAR
Enrollment	12 participants
Start Date	2025-12-03
Primary Completion	2028-12-30 (estimated)
Study Completion	2029-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-03